Comparative Performance of COVID-19 Test Methods in Healthcare Workers during the Omicron Wave
-
Published:2024-05-08
Issue:10
Volume:14
Page:986
-
ISSN:2075-4418
-
Container-title:Diagnostics
-
language:en
-
Short-container-title:Diagnostics
Author:
Tornberg Emma C.1, Tomlinson Alexander1, Oshiro Nicholas T. T.1ORCID, Derfalie Esraa1, Ali Rabeka A.1, Curlin Marcel E.1ORCID
Affiliation:
1. Department of Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR 97239, USA
Abstract
The COVID-19 pandemic presents unique requirements for accessible, reliable testing, and many testing platforms and sampling techniques have been developed over the course of the pandemic. Not all test methods have been systematically compared to each other or a common gold standard, and the performance of tests developed in the early epidemic have not been consistently re-evaluated in the context of new variants. We conducted a repeated measures study with adult healthcare workers presenting for SARS-CoV-2 testing. Participants were tested using seven testing modalities. Test sensitivity was compared using any positive PCR test as the gold standard. A total of 325 individuals participated in the study. PCR tests were the most sensitive (saliva PCR 0.957 ± 0.048, nasopharyngeal PCR 0.877 ± 0.075, oropharyngeal PCR 0.849 ± 0.082). Standard nasal rapid antigen tests were less sensitive but roughly equivalent (BinaxNOW 0.613 ± 0.110, iHealth 0.627 ± 0.109). Oropharyngeal rapid antigen tests were the least sensitive (BinaxNOW 0.400 ± 0.111, iHealth brands 0.311 ± 0.105). PCR remains the most sensitive testing modality for the diagnosis of COVID-19 and saliva PCR is significantly more sensitive than oropharyngeal PCR and equivalent to nasopharyngeal PCR. Nasal AgRDTs are less sensitive than PCR but have benefits in convenience and accessibility. Saliva-based PCR testing is a viable alternative to traditional swab-based PCR testing for the diagnosis of COVID-19.
Funder
OHSU Occupational Health Oregon Health Authority
Reference24 articles.
1. Use of At-Home COVID-19 Tests—United States, 23 August 2021–12 March 2022;Rader;MMWR Morb. Mortal. Wkly. Rep.,2022 2. Brummer, L.E., Katzenschlager, S., McGrath, S., Schmitz, S., Gaeddert, M., Erdmann, C., Bota, M., Grilli, M., Larmann, J., and Weigand, M.A. (2022). Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: An updated systematic review and meta-analysis with meta-regression analyzing influencing factors. PLoS Med., 19. 3. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection;Dinnes;Cochrane Database Syst. Rev.,2021 4. Performance of point-of care molecular and antigen-based tests for SARS-CoV-2: A living systematic review and meta-analysis;Fragkou;Clin. Microbiol. Infect.,2023 5. Bekliz, M.P.-R.F., Puhach, O., Adea, K., Melancia, S.M., and Baggio, S. (2022). Sensitivity of SARS-CoV-2 antigen-detecting rapid tests for Omicron variant. medRxiv.
|
|